RCRamona Clemen

Ramona Clemen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ramona Clemen has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ovalbumin oxidative modification fingerprints depend on gas plasma-driven reactive species profiles

    by Paul Schulan, Kristian Wende, Ramona Clemen, Torsten Gerling, Klaus-Dieter Weltmann, Klaus Ruhnau, Thomas von Woedtke, Michael Lalk, Sander Bekeschus

    Oxidative protein modifications have been linked to several diseases, but the variety and diversity of modifications are less studied. We used the chicken egg protein ovalbumin and gas plasma technology, a potent source of various reactive species, for protein oxidation. Using high-resolution mass spectrometry and an in-house workflow, over 80 distinct oxidative protein modifications were mapped at per-amino-acid resolution. To examine how modification profiles depend on changes in reactive species types and concentrations, we generated 12 distinct argon gas plasmas by systematically varying molecular gas admixtures (water, ethanol, oxygen, and nitrogen). Optical emission spectroscopy (OES) and photometric determination of deposited long-lived species (hydrogen peroxide, nitrite, and nitrate) were applied to profile gas plasma conditions, revealing the admixture-dependent impact on the reactive oxygen/nitrogen species (ROS/RNS) fingerprint. Correlation analysis with mass spectrometry data revealed the significant involvement of atomic oxygen and hydrogen peroxide in protein oxidation. The enrichment of specific reactive species created by a defined gas plasma composition generated specific ovalbumin oxidation profiles resolved per amino acid. Feed gas-dependent oxidation hotspots, such as Trp149 for dry argon gas or Met274 for hydroxyl radical-rich humidified argon gas, were identified. This first-of-its-kind study reveals intricate relationships between dynamic reactive species environments and protein oxidation profiles using ovalbumin as a model system.

  • Gas Plasma‐Derived Reactive Species for Oxidative and Biomaterial Modifications—Smart Chemistry Enabling Biomedical Applications

    by Mohsen Ahmadi, Kristian Wende, Klaus‐Dieter Weltmann, Ramona Clemen, Sander Bekeschus

    Cold gas plasma chemistry facilitates biological and medical applications through the generation of reactive oxygen and nitrogen species (ROS/RNS), which interact with both materials and biological systems. At the materials level, plasma‐derived reactive species modify surfaces such as hydrogels, scaffolds, nanomaterials, and inorganic substrates, thereby altering their physicochemical properties and improving how these materials interface with cells or tissues. At the biological level, reactive species can interact with (bio)molecules, ROS‐responsive biomaterials, and cellular pathways, modulating redox signaling, immune responses, or metabolic processes. These modes of action apply in different contexts: plasma can modify materials before biological use or influence biomaterials as well as cells and tissues as a biological stimulus or co‐therapeutic. This review covers recent advances in plasma‐induced chemical transformations and discusses the dual role of plasma as a molecular engineering platform and co‐therapeutic agent. Looking ahead, spatiotemporal control of ROS/RNS generation will be key not only for designing next‐generation functional materials but also for local programming of cells in situ by modulating signaling pathways, immunometabolism, and tissue microenvironments to facilitate on‐demand scaffold activation, selective antimicrobial/antitumor actions, and precision tissue regeneration. These capabilities highlight the growing promise of plasma technologies in advanced biomedicine.


  • Open Access

    Oxidized Melanoma Antigens Promote Activation and Proliferation of Cytotoxic T‐Cell Subpopulations

    by Ramona Clemen, Lea Miebach, Debora Singer, Eric Freund, Thomas von Woedtke, Klaus‐Dieter Weltmann, Sander Bekeschus

    Increasing evidence suggests the role of reactive oxygen and nitrogen species (RONS) in regulating antitumor immune effects and immunosuppression. RONS modify biomolecules and induce oxidative post‐translational modifications (oxPTM) on proteins that can alarm phagocytes. However, it is unclear if and how protein oxidation by technical means could be a strategy to foster antitumor immunity and therapy. To this end, cold gas plasma technology producing various RONS simultaneously to oxidize the two melanoma‐associated antigens MART and PMEL is utilized. Cold plasma‐oxidized MART (oxMART) and PMEL (oxPMEL) are heavily decorated with oxPTMs as determined by mass spectrometry. Immunization with oxidized MART or PMEL vaccines prior to challenge with viable melanoma cells correlated with significant changes in cytokine secretion and altered T‐cell differentiation of tumor‐infiltrated leukocytes (TILs). oxMART promoted the activity of cytotoxic central memory T‐cells, while oxPMEL led to increased proliferation of cytotoxic effector T‐cells. Similar T‐cell results are observed after incubating splenocytes of tumor‐bearing mice with B16F10 melanoma cells. This study, for the first time, provides evidence of the importance of oxidative modifications of two melanoma‐associated antigens in eliciting anticancer immunity.


  • Open Access

    Medical Gas Plasma Technology Combines with Antimelanoma Therapies and Promotes Immune‐Checkpoint Therapy Responses

    by Lea Miebach, Gabriella Melo‐Zainzinger, Eric Freund, Ramona Clemen, Alessandra Lourenco Cecchini, Sander Bekeschus

    Strategies to improve activity and selectivity are major goals in oncological drug development. Medical gas plasma therapy has been subject to intense research in dermatooncology recently. Based on partial gas ionization, this approach is exceptional in generating a variety of reactive oxygen species simultaneously that can be applied locally at the tumor side. It is hypothesized that combined gas plasma treatment can potentiate drug responses in the treatment of melanoma. Using a plasma jet approved as medical device in Europe, a systematic screening of 46 mitochondria‐targeted drugs identifies five agents synergizing in vitro and in vivo. Increased intratumoral leucocyte infiltration points to immunomodulatory aspects of the treatment, motivating to investigate responses to immune checkpoint blockade in combination with plasma. Tumor growth is monitored based on bioluminescent imaging, and single‐cell suspensions are retrieved from each tumor to characterize tumor‐infiltrating leucocytes using multicolor flow cytometry. Gene expression profiling is done using a validated NanoString panel targeting 770 genes specifically designed for immuno‐oncological research. Cell type abundancies are characterized from bulk RNA samples using the CIBERSORT computational framework. Collectively, the results indicate that local application of medical gas plasma technology synergizes with mitochondria‐targeted drugs and anti‐PD1 checkpoint therapy in treating melanoma.


  • Open Access

    Gas plasma technology optimization to target drug-resistant bacteria

    by Ramona Clemen, Lars Boeckmann, Steffen Emmert, Sander Bekeschus

  • Open Access

    Plasma, cancer, immunity

    by Sander Bekeschus, Ramona Clemen

    Albeit heavily investigated for several decades already, the importance of the immune system in targeting cancer has received wide clinical attention only in recent years. This is partly because of long-standing rather traditional concepts on tumor biology on the one hand and the complexity of the immune system and its processes on the other. The viewpoint of evaluating existing and emerging approaches in oncology based on toxicity to tumors and the ability to engage antitumor-immunity is gaining ground across several disciplines. Along those lines, cold physical plasma was suggested as potential anticancer tool more than a decade ago, but solid evidence of the immune system playing a role in plasma cancer treatment only emerged in recent years. Moreover, plasma may support cancer immunotherapies in the future. Cancer immunotherapies are systemic treatments with biologicals that were reported to synergize with existing local physical modalities before, such as radiotherapy and photodynamic therapy. This review outlines key concepts in oncology, immunology, and tumor therapy, links them to plasma research, and discusses immuno-oncological consequences. Finally, promising future clinical applications are summarized. Synoptically, first scientific evidence supports an immuno-oncological dimension of plasma cancer treatment in selected instances, but robust clinical evidence is still lacking. More basic and clinical research is needed to determine the immuno-molecular mechanisms and detailed plasma application modalities to facilitate real patient benefit in the long term.


  • Open Access

    Gas plasma–oxidized sodium chloride acts via hydrogen peroxide in a model of peritoneal carcinomatosis

    by Lea Miebach, Eric Freund, Ramona Clemen, Stephan Kersting, Lars-Ivo Partecke, Sander Bekeschus

    Gas plasma technology generates reactive oxygen and nitrogen species (ROS/RNS), inducing lethal oxidative damage in tumor cells. The transfer of gas plasma–derived ROS/RNS into liquids has been proposed as an innovative anti-cancer strategy targeting peritoneal carcinomatosis (PC). However, the mechanism of action is under debate. To this end, we compared gas plasma–oxidized medical-grade sodium chloride (oxNaCl) with a concentration-matched control (cmc) of NaCl enriched with equivalent concentrations of H 2 O 2 and NO 3 − in several cell lines and models of PC. Strikingly, oxNaCl and cmc performed equally well in oxidation and cytotoxic activity in tumor cells in two-dimensional cultures, three-dimensional (3D) tumor spheroids, vascularized 3D tumors grown on chicken-embryo chorioallantoic membranes, and a syngeneic PC mouse model in vivo. Given the importance of immunotherapies in oncology today, we focused on immunological consequences of the treatment. Again, to a similar extent, oxNaCl and cmc increased tumor cell immunogenicity and enhanced uptake by and maturation of peripheral blood monocyte–derived dendritic cells together with an inflammatory secretion profile. Furthermore, NanoString gene expression profiling revealed immune system processes and unfolded protein response-related pathways as being linked to the observed anti-tumor effects for both oxNaCl and cmc. In conclusion, gas plasma–generated oxNaCl and cmc showed equal therapeutic efficacy in our PC-related models. In light of the many promising anti-cancer studies of gas plasma–oxidized liquids and the convenient production of corresponding cmcs in large quantities as needed in clinics, our findings may spur research lines based on low-dose oxidants in peritoneal cancer therapy.


  • Open Access

    Singlet‐Oxygen‐Induced Phospholipase A2 Inhibition: A Major Role for Interfacial Tryptophan Dioxidation

    by Zahra Nasri, Seyedali Memari, Sebastian Wenske, Ramona Clemen, Ulrike Martens, Mihaela Delcea, Sander Bekeschus, Klaus‐Dieter Weltmann, Thomas von Woedtke, Kristian Wende

    Several studies have revealed that various diseases such as cancer have been associated with elevated phospholipase A2 (PLA2) activity. Therefore, the regulation of PLA2 catalytic activity is undoubtedly vital. In this study, effective inactivation of PLA2 due to reactive species produced from cold physical plasma as a source to model oxidative stress is reported. We found singlet oxygen to be the most relevant active agent in PLA2 inhibition. A more detailed analysis of the plasma‐treated PLA2 identified tryptophan 128 as a hot spot, rich in double oxidation. The significant dioxidation of this interfacial tryptophan resulted in an N‐formylkynurenine product via the oxidative opening of the tryptophan indole ring. Molecular dynamics simulation indicated that the efficient interactions between the tryptophan residue and phospholipids are eliminated following tryptophan dioxidation. As interfacial tryptophan residues are predominantly involved in the attaching of membrane enzymes to the bilayers, tryptophan dioxidation and indole ring opening leads to the loss of essential interactions for enzyme binding and, consequently, enzyme inactivation.